Education
About Us
Working with TipRanks
Follow Us
Cara Therapeutics (CARA)
NASDAQ:CARA
Total Valuation
Cara Therapeutics has a market cap or net worth of $22.41M. The enterprise value is $170.32M.
Market Cap$22.41M
Enterprise Value$170.32M
Share Statistics
Cara Therapeutics has 4,573,606 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,573,606
Owned by Insiders25.48%
Owned by Institutions5.71%
Financial Efficiency
Cara Therapeutics’s return on equity (ROE) is 15.43 and return on invested capital (ROIC) is -139.18%.
Return on Equity (ROE)15.43
Return on Assets (ROA)-1.62
Return on Invested Capital (ROIC)-139.18%
Return on Capital Employed (ROCE)-1.40
Revenue Per Employee713.70K
Profits Per Employee-7.09M
Employee Count10
Asset Turnover0.16
Inventory Turnover0.90
Valuation Ratios
The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio―
PS Ratio3.65
PB Ratio-25.32
Price to Fair Value-1.62
Price to FCF-5.78
Price to Operating Cash Flow-5.81
PEG Ratio-0.49
Income Statement
In the last 12 months, Cara Therapeutics had revenue of 7.14M and earned -70.87M in profits. Earnings per share was -46.59.
Revenue7.14M
Gross Profit6.33M
Operating Income-55.78M
Pretax Income-71.27M
Net Income-70.87M
EBITDA-62.60M
Earnings Per Share (EPS)-46.59
Cash Flow
In the last 12 months, operating cash flow was -35.16M and capital expenditures -210.00K, giving a free cash flow of -35.37M billion.
Operating Cash Flow-35.16M
Free Cash Flow-35.37M
Free Cash Flow per Share-7.73
Dividends & Yields
Cara Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.98
52-Week Price Change42.16%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
Cara Therapeutics upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Cara Therapeutics as a current ratio of 11.03, with Debt / Equity ratio of 0.00%
Current Ratio11.03
Quick Ratio10.81
Debt to Market Cap5.96
Net Debt to EBITDA-0.10
Interest Coverage Ratio-6.58
Taxes
In the past 12 months, Cara Therapeutics has paid -398.00K in taxes.
Income Tax-398.00K
Effective Tax Rate<0.01
Enterprise Valuation
Cara Therapeutics EV to EBITDA ratio is -0.22, with an EV/FCF ratio of -0.23.
EV to Sales1.96
EV to EBITDA-0.22
EV to Free Cash Flow-0.23
EV to Operating Cash Flow-0.23
Balance Sheet
Cara Therapeutics has $34.22M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$34.22M billion.
Cash & Marketable Securities$34.22M
Total Debt$0.00
Net Cash-$34.22M
Net Cash Per Share-$7.48
Tangible Book Value Per Share-$3.02
Margins
Gross margin is 78.80%, with operating margin of -781.57%, and net profit margin of -992.95%.
Gross Margin78.80%
Operating Margin-781.57%
Pretax Margin-998.53%
Net Profit Margin-992.95%
EBITDA Margin-877.12%
EBIT Margin-879.81%
Analyst Forecast
The average price target for Cara Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-65.96%
EPS Growth Forecast40.80%